AstraZeneca (LSE:AZN) has been back in the spotlight after new Phase III data for lung cancer drug IMFINZI and COPD biologic tozorakimab, as well as fresh approvals in breast cancer and HER2 positive disease.
The recent IMFINZI and tozorakimab updates slot into a busy few weeks for AstraZeneca, yet the share price has drifted. The 90-day share price return is 13.03% and the year-to-date share price return is 13.86%, while the 1-year total shareholder return is 0.97% and the 5-year total shareholder return is 61.14%. This points to long term holders still being ahead, while shorter term momentum has faded around a £117.08 print.
Scan AstraZeneca’s latest trial wins against a curated 8 healthcare AI stocks that could be building the next wave of breakthrough therapies in respiratory disease and oncology.
AstraZeneca now trades around £117 while sitting roughly 34% below the average analyst target and over 50% below some intrinsic value estimates. Is that a valuation gap, or a fair premium for execution risk and pipeline complexity?
Most Popular Narrative: 26.4% Undervalued
AstraZeneca’s most followed valuation story pegs fair value at £159.11, well above the last close at £117.08, which puts the recent share drift into a different context.
The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is set to deliver multiple blockbuster launches over the next several years. Management estimates these new medicines could generate $10+ billion in peak risk-adjusted revenue, directly supporting both long-term high-margin revenue growth and future earnings expansion.
Investors may want to see what kind of revenue curve and margin profile that pipeline is assumed to support. The fair value hinges on a specific earnings glide path and a premium P/E that many investors usually associate with faster growing sectors.
Result: Fair Value of £159.11 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, AstraZeneca’s reliance on a handful of blockbuster therapies and its rising exposure to government price controls could quickly challenge the view that the stock is 26.4% undervalued.
Find out about the key risks to this AstraZeneca narrative.
Next Steps
Sentiment on AstraZeneca is split, which gives you a clean chance to weigh the evidence yourself and decide how much risk and potential reward you see. To pressure test that view against the data, start with the balance of 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond AstraZeneca?
If AstraZeneca has sharpened your focus on quality, do not stop here. Broaden your watchlist with a few targeted ideas that could sharpen your next move.
- Spot potential mispricing early by scanning a curated pool of quality candidates through the 9 high quality undervalued stocks.
- Strengthen your income playbook by reviewing companies that feature in the 1 dividend fortresses.
- Lower your overall portfolio stress by filtering for sturdier balance sheets via the list of solid balance sheet and fundamentals (10 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com